Home » Newsletters » BioWorld Science

BioWorld Science

June 21, 2017

View Archived Issues

Medlab receives ethics approvals for trials of two cannabis-based medicines

Pfizer initiates phase I study of group B Streptococcus vaccine PF-06760805

Unum Therapeutics announces active IND for ACTR-707

NIAID grants support development of vaccines for Zika virus and river blindness

Biocad's BCD-055 demonstrates equivalence to infliximab in clinical trials

twoXAR's TXR-411 shows promise in mouse model of type 2 diabetes

Phase Ib results for infigratinib plus imatinib in patients with advanced GIST presented

Phase I/II results for cabiralizumab monotherapy in patients with tenosynovial giant cell tumor

Enrollment to begin in phase I/II trial of Ceplene for the treatment of CMML

Heidelberg Pharma and Takeda sign exclusive multitarget research agreement

Phase II results show beneficial effects of NT-501 in patients with macular telangiectasia type 2

Phase II study of glepaglutide in patients with short bowel syndrome meets primary endpoint

AbbVie's lutikizumab fails primary endpoint in a phase IIa trial for hand OA

SerImmune enters research and development collaboration with Merck & Co.

NCATS grants to fund use of Emulate's Human Emulation System on International Space Station

FDA approves Mydayis for adolescents and adults with ADHD

eFFECTOR enters collaboration to study EFT-508 with avelumab in colorectal cancer

Almac Discovery collaborates with Debiopharm on Wee-1 kinase inhibitor program

NINDS grant supports development of BlackThorn Therapeutics' KOR antagonist program

Nimbus Apollo presents acetyl-CoA carboxylase inhibitors

Icagen partners with Omdana on disorders related to tissue homeostasis and vascular remodeling

Shenzhen Targetrx Biotechnology discloses novel tyrosine kinase inhibitors

Seattle Genetics submits supplemental BLA for Adcetris in CTCL

Glenmark licenses small-molecule oncology compound from APC Therapeutics

A novel orally active ACC2-selective inhibitor improves glucose homeostasis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...